At MindMed, we’re dedicated to advancing mental health treatments through rigorous scientific research. Our approach features comprehensive trials, innovative research, and collaboration with top experts.

#EmployeeSpotlight 🌟 Meet Dan Gavin, our Head of Talent Acquisition. Dan brings a passion for science and a deep commitment to #MentalHealth to his work at MindMed. In today’s market, top talent isn’t looking for a job—they’re evaluating a mission. At MindMed, we’re not just

Our CEO Robert Barrow just wrapped a fireside chat at the @HCWCO Neuro Perspectives Conference where he shared how we’re forging a new era in psychiatry. From clinical innovation to scalable solutions, we’re focused on changing the way brain health disorders are treated. 🎥

Psychedelics are in the final stages of clinical development that could potentially allow for regulatory approval. Are you ready for it?. Our CMO Dan Karlin is joining an incredible panel at @IAmBiotech's #BIO2025 to talk about the future of novel therapies for anxiety and

We’re gearing up for @bmsnews’s Digital Breakthrough for Pharma Summit 2025 and couldn’t be more excited to be part of it! . BMS is bringing together leading voices from across pharma, digital medicine, and life sciences to explore how digital health innovation is reshaping

Our Director of Government Affairs, Gretchen Shaub, MPP, participated in the 5th Annual Psychedelic Therapeutics & Drug Development Conference panel, “Beyond Barriers – Navigating the Regulatory Landscape for Psychedelic Medicine.” . The panel moderated by Jon Kostas, Executive

We’re looking forward to participating in @Jefferies Global Healthcare Conference and @HCWCO 6th Annual Neuro Perspectives Hybrid Conference where our leadership will present a company overview highlighting the progress we are making towards potentially transforming the treatment

🎉 We are thrilled to welcome Brandi Roberts CPA as our new Chief Financial Officer! Ms. Roberts joins our executive leadership team, where she will lead financial strategy, capital planning, accounting, investor relations, and information technology. Her proven track record

#EmployeeSpotlight 🌟 Meet Noelle Bullard, our Associate General Counsel. At MindMed, Noelle provides legal strategy collaborating with cross-functional teams, supporting transition from early-stage clinical development to commercial readiness. Her expertise and dedication play a

We look forward to attending the @APApsychiatric Annual Meeting in Los Angeles! At MindMed, we’re taking an innovative approach to transforming the treatment landscape for #BrainHealth disorders. Connect with our team at booth #2200 to learn more about the progress we’re making.

We’re looking forward to attending the @rbccm Global Healthcare Conference. Find more information here: $MNMD

We published our Q1 2025 financial results and business updates today. A replay of this morning’s conference call is now available. Read the full press release here:

We were honored to be a sponsor of the 2025 Lifesavers Gala, hosted by @afspnational. This inspiring event recognized those making a difference in suicide prevention and raised vital funds for AFSP’s work in research, education, advocacy, and support in mental health care.

Recently, we joined the @PsychedelicsRX for a Congressional reception and met with members of Congress to discuss the future of prescription psychedelic medicines. We convened with policymakers, staff, scientific advisors, and industry leaders for a dialogue on the therapeutic

We will report our Q1 2025 financial results and business updates during a live webcast at 8:00am ET on May 8, 2025. See press release here for details to register:

A bold new chapter in mental health has arrived. We’ve officially launched our Phase 3 Emerge study evaluating our lead candidate in #MajorDepressiveDisorder (MDD), potentially transforming how we treat the second most common mental health disorder in the U.S.* . This isn’t

In case you missed it, we recently initiated our Phase 3 study to evaluate our lead candidate in #MajorDepressiveDisorder in addition to #GeneralizedAnxietyDisorder. These are the most common #BrainHealthDisorders in the U.S and often share some of the same symptoms and standard

Today, we announced that the first participant has been dosed in Emerge, the first Phase 3 study of lysergide D-tartrate (LSD) in #MajorDepressiveDisorder (MDD). The Emerge study will evaluate the efficacy and safety of MindMed’s lead product candidate versus placebo. This is a

A huge congratulations to our CEO Robert Barrow on being recognized as a @Citeline In Vivo Rising Leader! 🌟 This recognition is a powerful testament to Rob's visionary leadership in shaping the future of mental health. Under Rob’s leadership, MindMed is charting a course with

#EmployeeSpotlight 🌟 Meet Andrew Phelps, Senior Scientist in our Pharmaceutical Development department. He recently joined our team and has quickly become an integral part of ensuring our key program milestones are met with respect to analytical testing and providing technical

#EmployeeSpotlight 🌟 Meet Allan Morales, our Senior Clinical Trial Associate. Passionate about innovation in brain health, Allan is driven by the potential impact his work at MindMed could have on the quality of life of people living with brain health disorders. Every day, he